Bioengineering company FGen acquired by Ginkgo Bioworks

The ETH-spinoff FGen, a company specialised in the ultra-high-throughput analysis of cellular libraries, was acquired by Ginkgo Bioworks, a Boston-based platform for cell programming. Co-founded in 2011 by scientists from Sven Panke’s Bioprocess Lab, FGen designs and optimises biotechnological production strains for sustainable bio-based products. The acquisition represents another major step in D-BSSE’s goal of advancing bio-engineering technologies in life sciences worldwide.